Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04299880 · ClinicalTrials.gov registry record · Phase 1
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04299880 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 7 participants.
The verdict
NCT04299880, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated with napabucasin (monotherapy or combination) and who are deriving continued clinical benefit in the parent study at the time of closure.
Interventions
- DRUG Nivolumab
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Napabucasin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2021-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04299880
The ClinicalTrials.gov registry entry for NCT04299880 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT04299880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04299880 about?
NCT04299880 is a clinical study titled "Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols". This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated with napabucasin (monotherapy or combination) and who are deriving cont...
What is the current status of trial NCT04299880?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2020-02-24. Estimated completion is 2021-05-30.
What interventions are being tested in trial NCT04299880?
The interventions under investigation include: Nivolumab (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Napabucasin (DRUG).
Who is sponsoring clinical trial NCT04299880?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.